Jülich startup SRTD Biotech raises €31.5 million for precision mRNA therapies
SRTD Biotech, a Jülich-based biotech startup, secured €31.5 million in an oversubscribed seed funding round to advance next-generation precision mRNA therapeutics targeting diseased cells. The round was led by Mérieux Equity Partners alongside NRW.BANK and Boehringer Ingelheim Venture Fund, with other investors including Lilly Ventures and HTGF participating.
Why it matters
This significant funding will accelerate development of highly targeted mRNA treatments, potentially improving therapeutic precision and outcomes for various diseases.
Discussion
Loading discussion…
Anyone can vote. Approved members can comment. Log in